IP Library Granted Patent US 9,944,894
Granted Patent B2
US 9,944,894 · App. 14/956,408 · Granted Apr 17, 2018

Pluripotent stem cell expansion and passage using a rocking platform bioreactor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,944,894
App. No.
14/956,408
Granted
Apr 17, 2018
Kind
B2
Abstract

Provided herein are novel methods for expansion and passaging of cell aggregates comprising stem cells and/or differentiated cells and comprising the use of closed systems on rocking platform bioreactors. The methods of the invention permit closed system serial passage expansion of pluripotent stem cells and/or progeny thereof with associated pluripotency markers and differentiation potential.

Claims (33)

1. A method for culturing cells in a closed system, the method comprising:

providing the cells to a culture vessel on a rocking platform bioreactor, wherein the cells are capable of forming cell aggregates in suspension;

expanding the cells in a culture medium to generate the cell aggregates in suspension;

performing an automated perfusion of the culture medium, wherein the automated perfusion is performed in absence of a filtration system while retaining the cell aggregates within the culture vessel;

flowing the cell aggregates across an in-line slicer grid to generate sliced cell aggregates; and

passaging the sliced cell aggregates in the closed system,

wherein the cell aggregates are passed through a mixing device for mixing the cell aggregates prior to flowing the cell aggregates across the in-line slicer grid, and

wherein the mixing device is placed between the culture vessel and the in-line slicer grid in the closed system.

2. The method of claim 1 , wherein the cells are of plant, animal, insect, or microbial origin.

3. The method of claim 1 , wherein the cells comprise pluripotent stem cells or differentiated human cells.

4. The method of claim 1 , wherein the cell aggregates are retained within the culture vessel by allowing the cell aggregates to settle by gravity.

5. The method of claim 1 , wherein the automated perfusion is performed without human intervention.

6. The method of claim 1 , wherein the in-line slicer grid comprises blades that are separated by a distance from about 20 microns to about 500 microns.

7. The method of claim 1 , wherein the in-line slicer grid comprises blades that are separated by a distance of about 100 microns.

8. The method of claim 1 , wherein the in-line slicer grid is coated with or comprises a hydrophobic material.

9. The method of claim 1 , wherein an average diameter of the cell aggregates is no more than 800 microns.

10. A method for culturing cells in a closed system, the method comprising:

providing the cells in a culture vessel on a rocking platform bioreactor, wherein the cells are capable of forming cell aggregates in suspension;

expanding the cells in a culture medium to generate the cell aggregates in suspension;

performing an automated perfusion of the cell culture medium while retaining the cell aggregates within the closed system, wherein the cell aggregates are retained within the closed system by allowing gravity settling of the cell aggregates;

flowing the cell aggregates across an in-line slicer grid to generate sliced cell aggregates; and

passaging the sliced cell aggregates in the closed system, wherein the cell aggregates are passed through a mixing device for mixing the cell aggregates prior to flowing the cell aggregates across the in-line slicer grid, and

wherein the mixing device is placed between the culture vessel and the in-line slicer grid in the closed system.

11. The method of claim 10 , wherein the culture vessel further comprises a tubing assembly comprising a dip tube and a gravity settling chamber.

12. The method of claim 11 , wherein the cell aggregates are retained within the gravity settling chamber.

13. The method of claim 10 , wherein the automated perfusion is performed in the absence of a filtration system.

14. The method of claim 10 , wherein flowing the cell aggregates across the in-line slicer grid is performed at flow rates from about 15 mL/min to about 150 mL/min.

15. The method of claim 10 , wherein the in-line slicer grid comprises blades that are separated by a distance from about 20 microns to about 500 microns.

16. The method of claim 15 , wherein the in-line slicer grid comprises blades that are separated by a distance of about 100 microns.

17. The method of claim 10 , wherein the step of passaging the sliced cell aggregates comprises culturing the sliced cell aggregates in absence of a ROCK inhibitor.

18. The method of claim 17 , wherein the sliced cell aggregates comprise pluripotent stem cells.

19. The method of claim 10 , wherein an average diameter of the cell aggregates is no more than 800 microns.

20. The method of claim 1 , wherein the in-line slicer grid is a polygonal slicer grid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2020
From: GENERAL ELECTRIC COMPANY
To: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC
Reel/Frame 053966/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2015
From: DAVIS, BRIAN MICHAEL; CONWAY, KENNETH ROGER; LOGHIN, EVELINA ROXANA; ZHANG, XIAOHUA
To: GENERAL ELECTRIC COMPANY
Reel/Frame 037206/0486 →